Celon Pharma SA Total Assets
Celon Pharma SA total assets. Based on the latest financial reports, Celon Pharma SA (CLN) holds total assets worth zł670.73 Million PLN (≈ $184.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CLN cash flow metrics for how efficiently the company converts equity into cash flow.
Total Assets of Celon Pharma SA (2012–2025)
Total assets of Celon Pharma SA from 2012 to 2025. This chart illustrates how Celon Pharma SA's total assets have evolved over time, based on quarterly financial data. See CLN live share price for real-time trading data and today's change.
Celon Pharma SA - Asset Composition Analysis
Celon Pharma SA Total Assets Breakdown (December 2025)
Celon Pharma SA total assets breakdown as of December 2025. Celon Pharma SA's total assets of zł670.73 Million consist of 22.4% current assets and 77.7% non-current assets. Explore CLN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 4.2% |
| Accounts Receivable | zł52.17 Million | 11.4% |
| Inventory | zł26.11 Million | 5.7% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł15.69 Million | 3.4% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Celon Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celon Pharma SA's current assets represent 22.4% of total assets in 2025, a decrease from 25.2% in 2012.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2025, down from 8.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 11.4% of total assets.
Celon Pharma SA Competitors by Total Assets
Key competitors of Celon Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Celon Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 2.03 | 1.00 |
| Quick Ratio | 0.92 | 1.61 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł17.85 Million | zł74.34 Million | zł438.00K |
Celon Pharma SA - Advanced Valuation Insights
This section examines the relationship between Celon Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -15.9% |
| Total Assets | zł457.46 Million |
| Market Capitalization | $201.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Celon Pharma SA's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Celon Pharma SA's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celon Pharma SA (2012–2025)
The table below shows the annual total assets of Celon Pharma SA from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł457.46 Million ≈ $125.90 Million |
-15.88% |
| 2024-12-31 | zł543.79 Million ≈ $149.66 Million |
-4.48% |
| 2023-12-31 | zł569.31 Million ≈ $156.68 Million |
-6.51% |
| 2022-12-31 | zł608.93 Million ≈ $167.59 Million |
-13.89% |
| 2021-12-31 | zł707.14 Million ≈ $194.61 Million |
+0.50% |
| 2020-12-31 | zł703.64 Million ≈ $193.65 Million |
+18.99% |
| 2019-12-31 | zł591.35 Million ≈ $162.75 Million |
+4.91% |
| 2018-12-31 | zł563.67 Million ≈ $155.13 Million |
+7.36% |
| 2017-12-31 | zł525.05 Million ≈ $144.50 Million |
+13.08% |
| 2016-12-31 | zł464.32 Million ≈ $127.79 Million |
+175.91% |
| 2015-12-31 | zł168.29 Million ≈ $46.32 Million |
+59.61% |
| 2014-12-31 | zł105.44 Million ≈ $29.02 Million |
+27.66% |
| 2013-12-31 | zł82.59 Million ≈ $22.73 Million |
+18.33% |
| 2012-12-31 | zł69.80 Million ≈ $19.21 Million |
-- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.